B2M and cancer: The downregulation of B2M, a component of the MHC class I molecule necessary for tumor antigen presentation, provides further evidence to support that constitutive NRF2 activity in this GEMM may have both oncogenic and immunoevasive properties, a phenomenon that has been recently reported in human cancers (53).